FealtySign in
Promise-keeping streak3 kept in a rowguidance & buyback

Merck & Co., Inc.

(MRK)

CIK 310158 · SEC filings only

Not gradedDividend record
shown as history
company entity
55 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

55 declarations · 15 raised · 36 held · 0 cut · held 51 quarters

  1. HELD$0.8500/shperiod ended 2026-06-30Filing ↗
  2. RAISED$0.8500/shperiod ended 2026-03-31Filing ↗
  3. HELD$0.8100/shperiod ended 2025-09-30Filing ↗
  4. HELD$0.8100/shperiod ended 2025-06-30Filing ↗
  5. RAISED$0.8100/shperiod ended 2025-03-31Filing ↗
  6. HELD$0.7700/shperiod ended 2024-09-30Filing ↗
  7. HELD$0.7700/shperiod ended 2024-06-30Filing ↗
  8. RAISED$0.7700/shperiod ended 2024-03-31Filing ↗
  9. HELD$0.7300/shperiod ended 2023-09-30Filing ↗
  10. HELD$0.7300/shperiod ended 2023-06-30Filing ↗
  11. RAISED$0.7300/shperiod ended 2023-03-31Filing ↗
  12. HELD$0.6900/shperiod ended 2022-09-30Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
CGuidance record
grade
company entity
12 resolved promises

Sector median (Life Sciences): B across 7 graded companies

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance by basis

7 of 19 guidance figures that were graded or dropped for basis could not be graded on the same basis (37%). Guidance marked “not judged” is in neither number.

Guidance typeSaidGradedDroppedOther
Revenue · basis not stated217014
EPS · GAAP10505
EPS · non-GAAPcannot be graded200713

Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.

How the site-wide rate is measured

Compare across companies

Guidance shown, not graded (20)

We show what was said — with its source filing — but never score it. The line under each statement says why.

  1. eps guidance fy · Aug 4, 2026
    now expects full-year 2026 non-GAAP EPS to be between $2.66 and $2.76
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Feb 3, 2026
    Expects Non-GAAP EPS To Be Between $5.00 and $5.15
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Oct 30, 2025
    Raises and Narrows Expected Non-GAAP EPS Range To Be Between $8.93 and $8.98
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Jul 29, 2025
    Narrows Expected Non-GAAP EPS Range To Be Between $8.87 and $8.97
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Apr 24, 2025
    Now Expects Non-GAAP EPS To Be Between $8.82 and $8.97
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Feb 4, 2025
    Expects Non-GAAP EPS To Be Between $8.88 and $9.03
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Oct 31, 2024
    Now Expects Non-GAAP EPS To Be Between $7.72 and $7.77
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Apr 25, 2024
    Merck now expects its full-year non-GAAP EPS to be between $8.53 and $8.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Feb 1, 2024
    Expects Non-GAAP EPS To Be Between $8.44 and $8.59
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Aug 1, 2023
    Now Expects Non-GAAP EPS To Be Between $2.95 and $3.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Apr 27, 2023
    Merck is raising and narrowing its full-year 2023 non-GAAP EPS range to be between $6.88 and $7.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Feb 2, 2023
    Merck expects full-year 2023 non-GAAP EPS to be between $6.80 and $6.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Jul 28, 2022
    Merck is narrowing its expected full-year 2022 non-GAAP EPS range to be between $7.25 and $7.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Apr 28, 2022
    raising and narrowing its full-year 2022 non-GAAP EPS range to be between $7.24 and $7.36
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Feb 3, 2022
    Expects Non-GAAP EPS to be Between $7.12 and $7.27
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Oct 28, 2021
    full-year 2021 to be between $5.65 and $5.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Jul 29, 2021
    Expects Full-Year 2021 Non-GAAP EPS to be Between $5.47 and $5.57
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Feb 4, 2021
    Merck expects full-year 2021 non-GAAP EPS to be between $6.48 and $6.68
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Oct 27, 2020
    Merck narrowed and raised its full-year 2020 non-GAAP EPS range to be between $5.91 and $6.01
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · Apr 30, 2019
    Merck narrowed and raised its full-year 2019 non-GAAP EPS range to be between $4.67 and $4.79
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (1) · 18 superseded

Open · revenue guidance fy

now anticipates full-year 2026 sales to be between $66.3 billion and $67.3 billion

resolves in ~155 daysreceipt (opens in a new tab)
Superseded · revenue guidance fy

Merck now expects its full-year 2024 sales to be between $63.1 billion and $64.3 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Expects Full-Year 2022 GAAP EPS to be Between $5.76 and $5.91

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

raising and narrowing its full-year 2022 GAAP EPS range to be between $5.90 and $6.02

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Anticipates Worldwide Sales To Be Between $64.1 Billion and $65.6 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Expects Full-Year 2021 GAAP EPS to be Between $4.24 and $4.34

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Merck expects full-year 2023 GAAP EPS to be between $5.86 and $6.01

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Now Expects Sales To Be Between $65.8 Billion and $67.0 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Anticipates Full-Year 2023 Worldwide Sales To Be Between $57.2 Billion and $58.7 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Narrows and Raises Estimated Full-Year 2021 Revenue Range to be Between $46.4 Billion and $47.4 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Anticipates Worldwide Sales To Be Between $62.7 Billion and $64.2 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Merck expects full-year 2021 GAAP EPS to be between $5.52 and $5.72

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Narrows Expected Worldwide Sales Range To Be Between $64.3 Billion and $65.3 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Anticipates Worldwide Sales To Be Between $65.5 Billion and $67.0 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Merck now expects full-year 2023 sales to be between $57.7 billion and $58.9 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

full-year revenue estimated to be between $56.9 billion and $58.1 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Continues To Expect Worldwide Sales To Be Between $64.1 Billion and $65.6 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Merck anticipates full-year 2021 revenue to be between $51.8 billion and $53.8 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Anticipates Full-Year 2022 Worldwide Sales to be Between $56.1 Billion and $57.6 Billion

revised by a later guidancereceipt (opens in a new tab)

Credibility timeline

ABOVE · Feb 26, 2020BELOW · Feb 26, 2020BELOW · Feb 25, 2021IN LINE · Feb 25, 2021ABOVE · Feb 25, 2022ABOVE · Feb 25, 2022BELOW · Feb 24, 2023ABOVE · Feb 24, 2023ABOVE · Feb 26, 2024BELOW · Feb 26, 2024ABOVE · Feb 25, 2025ABOVE · Feb 24, 2026
20202026
Timeline as a list
  • Feb 26, 2020ABOVEMerck narrowed and raised its full-year 2019 revenue range to be between $43.9 billion and $45.1 billion
  • Feb 26, 2020BELOWMerck narrowed and raised its full-year 2019 GAAP EPS range to be between $4.02 and $4.14
  • Feb 25, 2021BELOWMerck narrowed and lowered its full-year 2020 GAAP EPS range to be between $4.55 and $4.65
  • Feb 25, 2021IN LINEMerck narrowed and raised its full-year 2020 revenue range to be between $47.6 billion and $48.6 billion
  • Feb 25, 2022ABOVEfull-year 2021 GAAP EPS range to be between $4.71 and $4.76
  • Feb 25, 2022ABOVEfull-year 2021 revenue estimated to be between $47.4 billion and $47.9 billion
  • Feb 24, 2023BELOWMerck expects its estimated full-year 2022 GAAP EPS to be between $5.89 and $5.99
  • Feb 24, 2023ABOVECompany Raises and Narrows Expected Full-Year 2022 Worldwide Sales Range To Be Between $57.5 Billion and $58.5 Billion
  • Feb 26, 2024ABOVERaises and Narrows Expected Worldwide Sales Range To Be Between $58.6 Billion and $59.6 Billion
  • Feb 26, 2024BELOWMerck is lowering and narrowing its full-year 2023 GAAP EPS range to be between $5.85 and $5.97
  • Feb 25, 2025ABOVENarrows Expected Worldwide Sales Range To Be Between $63.6 Billion and $64.1 Billion
  • Feb 24, 2026ABOVENow Expects Worldwide Sales To Be Between $64.5 Billion and $65.0 Billion
12 resolved guidance promises · 20 not graded (no comparable reported figure) · resolver resolver-v5 · score score-v1. Every verdict links to its source filing. Full methodology →